No Data
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading
European equities traded in the US as American depositary receipts opened the week slightly higher Monday morning, rising 0.12% to 1,429.79 on the S&P Europe Select ADR Index. From continental Europe,
Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Ionis Pharmaceuticals (IONS) and Ultragenyx Pharmaceutical (RARE)
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading
European equities traded in the US as American depositary receipts were trending modestly higher late Friday morning, rising 0.29% to 1,426.43 on the S&P Europe Select ADR Index. The index is set to c
Adaptimmune Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/17/2024 158.62% Mizuho $9 → $3 Maintains Buy 08/10/2023 -13.79% Barclays $2 → $1 Maintains Underweight
Mizuho Slashes Price Target on Adaptimmune Therapeutics to $3 From $9, Keeps Buy Rating
Adaptimmune Therapeutics (ADAP) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $1 to $4.
Express News | Adaptimmune Therapeutics PLC : Mizuho Cuts Target Price to $3 From $9